CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis
Novo Nordisk ObesityWeek data show CagriSema users who lost 5% by week 8 reached 25.4% weight loss at 68 weeks, ahead of an FDA decision due in Q4 2026.
CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis
Novo Nordisk ObesityWeek data show CagriSema users who lost 5% by week 8 reached 25.4% weight loss at 68 weeks, ahead of an FDA decision due in Q4 2026.
Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea
Lilly’s ObesityWeek 2026 slate: EloraTZP up to 23.3% weight loss in type 2 diabetes, retatrutide cuts sleep apnea events by up to 60.6%, Zepbound data in teens.
Heidi Overton FDA Vote: One GOP Defection Could Sink the Commissioner Pick
The Senate HELP Committee votes on FDA commissioner nominee Heidi Overton on 18 November. Here is where senators stand, why pharma is watching and what happens if she stalls.
Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight
Novo-backed Windward Bio raised $175M in its Nasdaq IPO, plus $50M from Sanofi, to fund WIN378, an anti-TSLP antibody aimed at twice-yearly dosing in asthma and COPD.
AstraZeneca Job Cuts: 600 US Sales Roles Go in $1.5B Savings Drive
AstraZeneca is cutting about 600 US respiratory and immunology sales jobs, Bloomberg reports, the first visible step in its $1.5 billion-a-year savings plan.
China NRDL 2026: Pfizer and Innovent GLP-1s Win Coverage as 107 Drugs Join
China’s 2026 reimbursement list adds 107 drugs, including Pfizer’s ecnoglutide and Innovent’s mazdutide for diabetes, from 1 January 2027.
Gazyva Membranous Nephropathy Approval: Roche Wins First FDA Nod in PMN
FDA approves Roche Gazyva as the first drug for primary membranous nephropathy after MAJESTY showed 36% complete remission vs 6% with tacrolimus.
Imfinzi Padcev Bladder Cancer Approval: AstraZeneca Takes On Keytruda in Cisplatin-Free Surgery Setting
The FDA approved perioperative Imfinzi plus Padcev for muscle-invasive bladder cancer patients who cannot take cisplatin. VOLGA cut the risk of death by 42%, and the approval pits AstraZeneca against Merck while Padcev wins either way.
Deramiocel FDA Decision: Capricor Trims Staff as Nov 22 DMD Verdict Nears
Capricor cut about 10% of staff and is preparing a solo launch ahead of the November 22 FDA decision on deramiocel for Duchenne muscular dystrophy.
